Price
540.85
-0.47%52W Range
Market Cap
₹2,389.43 Cr
Traded: ₹3.16 Cr (0.13%) 0.0x
Free Float: ₹689.59 Cr (0.46% of FF traded)
Volume · 60D trend
58.24 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | -- | +58.0% | -- | +134.0% | Accelerating |
| Profit | -- | -- | +48.0% | -- | -1.0% | Decelerating |
| Return | -- | -- | -- | -- | -- | -- |
| ROE | -- | -- | +9.0% | -- | -- | -- |
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025 | Jun 2025 | |
|---|---|---|---|---|
| Sales | 179 | 198 | 96 | 33 |
| Expenses | 155 | 172 | 100 | 29 |
| Operating Profit | 24 | 26 | -4 | 5 |
| OPM % | 13.2% | 13.2% | -3.7% | 14.2% |
| Other Income | 4 | 3 | 3 | 1 |
| Interest | 9 | 8 | 5 | 2 |
| Depreciation | 8 | 8 | 6 | 1 |
| Profit Before Tax | 10 | 12 | -12 | 2 |
| Tax % | 19.0% | -6.1% | -42.6% | 29.5% |
| Net Profit | 8 | 13 | -7 | 1 |
| Exceptional Items | -- | -- | -- | -- |
| EPS (Rs) | 1.8 | 3.0 | -1.8 | 0.5 |
| Sales Growth (YoY) | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | 106.3% | -- | -- |
| OP Growth (YoY) | 396.2% | -- | -- | -- |
| OP Growth (QoQ) | -9.9% | 833.1% | -- | -- |
| Profit Growth (YoY) | 458.0% | -- | -- | -- |
| EPS Growth (YoY) | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 265.6% | -- | -- |
| OP Margin | -- | 13.1% | -4.2% | -- |
| Net Margin | -- | 6.6% | -7.3% | -- |
| Material Cost % | 59.0% | 63.0% | 64.0% | 65.0% |
| Employee Cost % | 6.0% | 6.0% | 11.0% | 10.0% |
| P/S | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- |
| P/B | 4.87 | 5.16 | -- | -- |
Exchange Filings
42Submission of Newspaper Publication in Form PAS-1 for change or variation in the objects of utilisation of IPO Proceeds.
Newspaper Publication of Notice of 25th Annual General Meeting of the Comapny for FY2025-26.
Book closure intimation for 25th Annual General Meeting
Annual Report of the company for FY 2025-26
Notice of 25th Annual General Meeting for the Financial Year 2025-26 scheduled to be held on 10th September, 2026.
Transcript of Earnings Call held on 12th August, 2026 at 02:30 PM (IST) for Quarter 1 of FY 2026-27.
Audio Recording of the Earnings call held on 12th August, 2026
Investor Presentation Q1 FY 2027
Press Release
Statement on deviation or varition of funds
Announcement under Regulation 30 (LODR)- Change in Management
Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30.06.2026.
Outcome of Board Meeting held on 11th August, 2026 at the registered office of the company.
The Q1 earnings conference call for the FY 2026-27 is scheduled to be held on 12th August, 2026.
Sai Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve 1. Un-audited Financial Results ....
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30.06.2026
Outcome of the Board Meeting
Outcome of Board Meeting
Press Release
Announcement under Regulation 30 (LODR)
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Closure of trading window for the quarter ending on 30th June, 2026
Earnings Call Transcript
Receipt of Order
Audio recording
Investor Presentation
With reference to the subject cited, this is to inform the Exchanges that the Board Meeting of Sai Parenterals Limited held on Saturday, the 23rd day of May, 2026 at 11:30 a.m. at the Registered ....
Un Audited financial results (Standalone and Consolidated) for the quarter and nine months ended 31.12.2025
Press Release on the standalone & consolidated Audited financial results for the Quarter and Year ended 31.03.2026
Schedule of Q4 & FY 2025-26 Earnings Conference Call.
Statement on Deviation or Variation of funds
Audited Financial Results (Standalone and Consolidated) for the Quarter and Year ended 31.03.2026
Sai Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2026 ,inter alia, to consider and approve 1. Un-audited financial results ....
Monitoring Agency Report
Results- Delay in financial Results
Outcome of Board Meeting
Sai Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/04/2026 ,inter alia, to consider and approve INTIMATION OF BOARD MEETING ....
Intimation under Regulation 30(5) of SEBI
Intimation of Closure of Trading Window
Held by Mutual Funds
2 schemes hold SAIPARENT · sorted by weight